Id: acc4801
Group: 1sens
Protein: NF-kappaB p65
Gene Symbol: RELA
Protein Id: Q04206
Protein Name: TF65_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Immune system diseases
Disease: Atopic Dermatitis
Disease Subtype:
Disease Cellline: HaCaT?
Disease Info:
Drug: Rosa davurica Pall.
Drug Info: Rosa davurica Pall. is a type of plant that may have certain pharmacological properties and is used in traditional medicine.
Effect: modulate
Effect Info: "RDL pretreatment inhibits the activation of NF-κB by reducing p-IκB and p-NF-κB, thereby suppressing the inflammatory response."
Note:
Score: 4.0
Pubmed(PMID): 34455178
Sentence Index:
Sentence:

Sequence & Structure:

MDELFPLIFPAEPAQASGPYVEIIEQPKQRGMRFRYKCEGRSAGSIPGERSTDTTKTHPTIKINGYTGPGTVRISLVTKDPPHRPHPHELVGKDCRDGFYEAELCPDRCIHSFQNLGIQCVKKRDLEQAISQRIQTNNNPFQVPIEEQRGDYDLNAVRLCFQVTVRDPSGRPLRLPPVLSHPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTGPGWEARGSFSQADVHRQVAIVFRTPPYADPSLQAPVRVSMQLRRPSDRELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLSQISS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
RELA EDASALONEXENT Nuclear factor NF-kappa-B complex inhibitor 3 Terminated Duchenne muscular dystrophy ClinicalTrials
RELA EDASALONEXENT Nuclear factor NF-kappa-B complex inhibitor 3 Completed Duchenne muscular dystrophy ClinicalTrials
RELA EDASALONEXENT Nuclear factor NF-kappa-B complex inhibitor 1 Completed type 2 diabetes mellitus ClinicalTrials
RELA EDASALONEXENT Nuclear factor NF-kappa-B complex inhibitor 1 Completed Duchenne muscular dystrophy ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

RELA-Ser112
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.367
GBM
HNSC
LUAD
LUSC 0.765
non_ccRCC
PDAC
UCEC -1.132
RELA-Ser177
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.675
GBM -0.474
HNSC
LUAD -0.6
LUSC -0.083
non_ccRCC 1.626
PDAC
UCEC -1.143
RELA-Ser200
Cancer Intensity
BRCA
COAD 0.131
HGSC -2.56
ccRCC 0.526
GBM 0.516
HNSC 0.416
LUAD
LUSC 0.737
non_ccRCC -0.008
PDAC 0.386
UCEC -0.143
RELA-Ser202
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 1.142
HNSC -0.719
LUAD -0.423
LUSC
non_ccRCC
PDAC
UCEC
RELA-Ser235
Cancer Intensity
BRCA -0.452
COAD -0.397
HGSC 2.387
ccRCC -0.206
GBM -0.643
HNSC 0.08
LUAD -0.689
LUSC 0.666
non_ccRCC
PDAC
UCEC -0.747
RELA-Ser42
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.381
GBM -1.76
HNSC 0.615
LUAD 0.173
LUSC
non_ccRCC
PDAC
UCEC 0.591
RELA-Ser45
Cancer Intensity
BRCA
COAD
HGSC -0.868
ccRCC -0.94
GBM
HNSC 1.524
LUAD
LUSC
non_ccRCC
PDAC 0.148
UCEC 0.137

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - A Breast cancer Ubiquitination 34465889
- - D Perioperative neurocognitive disorder Acetylation 37591120
- - P Colon cancer/carcinoma Phosphorylation 23264896
- - U Colorectal cancer Glycosylation 32905539
- - U Bipolar disorder Phosphorylation 24075327

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: